AstraZeneca will co-develop stem cell drugs for diabetic blindness

09/12/2010 | Guardian (London), The

AstraZeneca signed a three-year research agreement with the University College London's Institute of Ophthalmology to discover and develop stem-cell-based drugs to treat diabetic retinopathy. "We're getting very keen on the whole area of regenerative medicines, and they will be part of our research development over the next few years," an AstraZeneca official said.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC